Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Stock Has Average Target Price of $53.00 According to Brokerages

Key Points

• Analysts rate Immunocore a “Moderate Buy” overall: Of 10 brokerages, five rate it Buy, one Strong Buy, three Hold, and one Sell. The average 12-month price target is $53.
• Quarterly results missed expectations: Immunocore reported a loss of $0.28 per share versus the $0.17 loss analysts expected, while revenue of $102.22 million fell short of the $152.09 million consensus.
• Institutional investors own 84.5% of the company’s shares, and several reported increasing or initiating positions in recent quarters.

Shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten brokerages that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $53.00.

A number of equities research analysts have weighed in on the stock. TD Cowen upgraded shares of Immunocore to a "strong-buy" rating in a research note on Monday, August 24th. Zacks Research cut Immunocore from a "strong-buy" rating to a "hold" rating in a research report on Thursday, September 3rd. HC Wainwright cut their price target on Immunocore from $100.00 to $80.00 and set a "buy" rating for the company in a research note on Tuesday. Mizuho increased their price objective on shares of Immunocore from $34.00 to $35.00 and gave the stock a "neutral" rating in a research note on Monday, August 3rd. Finally, Weiss Ratings restated a "sell (e+)" rating on shares of Immunocore in a research report on Thursday, October 15th.

Immunocore Trading Up 2.0%

NASDAQ:IMCR opened at $32.38 on Wednesday. The company has a current ratio of 4.62, a quick ratio of 4.44 and a debt-to-equity ratio of 0.94. Immunocore has a 12 month low of $27.50 and a 12 month high of $40.71. The company has a 50-day moving average price of $31.46 and a 200-day moving average price of $31.70. The stock has a market cap of $1.67 billion, a price-to-earnings ratio of -49.81 and a beta of 0.82.

Immunocore (NASDAQ:IMCR - Get Free Report) last announced its earnings results on Friday, November 6th. The company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.11). The business had revenue of $102.22 million for the quarter, compared to the consensus estimate of $152.09 million. Immunocore had a negative net margin of 7.48% and a negative return on equity of 7.96%. Equities analysts predict that Immunocore will post -0.04 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. GAMMA Investing LLC increased its stake in Immunocore by 202.8% in the 2nd quarter. GAMMA Investing LLC now owns 1,920 shares of the company's stock worth $61,000 after buying an additional 1,286 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in Immunocore in the 3rd quarter worth approximately $72,000. Juncture Wealth Strategies LLC purchased a new stake in Immunocore during the 3rd quarter valued at approximately $207,000. denkapparat Operations GmbH purchased a new stake in Immunocore during the 2nd quarter valued at approximately $209,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Immunocore by 27.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,252 shares of the company's stock valued at $285,000 after buying an additional 1,975 shares in the last quarter. Hedge funds and other institutional investors own 84.50% of the company's stock.

Immunocore Company Profile

Immunocore is a biotechnology company that develops T cell receptor (TCR)-based medicines for cancer and other diseases. Its ImmTAX platform is designed to create therapies that direct the body's T cells toward targets inside cells, including targets that may be difficult for conventional antibody treatments to reach. The company's marketed medicine, KIMMTRAK (tebentafusp-tebn), is a TCR-based therapy approved in the United States and other markets for certain patients with unresectable or metastatic uveal melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.